- Tracy, Maxwell;
- Lee, Mitchell;
- Hearn, Brady;
- Dowsett, Ian;
- Thurber, Luke;
- Loo, Jason;
- Loeb, Anisha;
- Preston, Kent;
- Tuncel, Miles;
- Ghodsian, Niloufar;
- Bode, Anna;
- Tang, Thao;
- Chia, Andy;
- Herr, Alan
Mutations affecting DNA polymerase exonuclease domains or mismatch repair (MMR) generate mutator phenotypes capable of driving tumorigenesis. Cancers with both defects exhibit an explosive increase in mutation burden that appears to reach a threshold, consistent with selection acting against further mutation accumulation. In Saccharomyces cerevisiae haploid yeast, simultaneous defects in polymerase proofreading and MMR select for antimutator mutants that suppress the mutator phenotype. We report here that spontaneous polyploids also escape this error-induced extinction and routinely outcompete antimutators in evolved haploid cultures. We performed similar experiments to explore how diploid yeast adapt to the mutator phenotype. We first evolved cells with homozygous mutations affecting polymerase δ proofreading and MMR, which we anticipated would favor tetraploid emergence. While tetraploids arose with a low frequency, in most cultures, a single antimutator clone rose to prominence carrying biallelic mutations affecting the polymerase mutator alleles. Variation in mutation rate between subclones from the same culture suggests that there exists continued selection pressure for additional antimutator alleles. We then evolved diploid yeast modeling MMR-deficient cancers with the most common heterozygous exonuclease domain mutation (POLE-P286R). Although these cells grew robustly, within 120 generations, all subclones carried truncating or nonsynonymous mutations in the POLE-P286R homologous allele (pol2-P301R) that suppressed the mutator phenotype as much as 100-fold. Independent adaptive events in the same culture were common. Our findings suggest that analogous tumor cell populations may adapt to the threat of extinction by polyclonal mutations that neutralize the POLE mutator allele and preserve intratumoral genetic diversity for future adaptation.